W. De Wispelaere

Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types?

D. Lambrechts, F. Amant, D. Annibali, 2021, Cancers.

Serine metabolism remodeling after platinum-based chemotherapy identifies vulnerabilities in a subgroup of resistant ovarian cancers

P. Carmeliet, H. Horlings, D. Lambrechts, 2022, Nature Communications.

The Expression of the Immunoproteasome Subunit PSMB9 Is Related to Distinct Molecular Subtypes of Uterine Leiomyosarcoma

F. Amant, G. D. de Souza, J. E. D. de Souza, 2022, Cancers.

Next generation point-of-care test for therapeutic drug monitoring of adalimumab in patients diagnosed with autoimmune diseases.

S. Vermeire, J. Lammertyn, D. Spasic, 2022, Biosensors & bioelectronics.

2022-RA-953-ESGO Serine metabolism remodeling after platinum-based chemotherapy is a new vulnerability in resistant ovarian cancer patients

H. Horlings, R. Agami, F. Amant, 2022, Ovarian cancer.

Chemotherapy-driven de novo Wnt pathway activation dictates a dynamic shift to a drug-tolerant state in breast cancer cells

C. Desmedt, D. Annibali, S. Soenen, 2024, bioRxiv.

PI3K/mTOR inhibition induces tumour microenvironment remodelling and sensitises pS6high uterine leiomyosarcoma to PD‐1 blockade

D. Lambrechts, D. Annibali, B. Boeckx, 2024, Clinical and translational medicine.